Global Overview of Orphan Drug Market
Disease that have low prevalence rates are no less important than ones that have a higher incidence. Few of the countries have laws to determine the treatment and approach to orphan disease, and there are criteria that establish whether or not a disease can be classified in the first place. In Japan, a disease that affects less than 50,000 persons is an orphan disease. In US, this number is 200,000.1
Orphan drugs is a niche buster because they provide an ideal venue for companies to offset the lapsing patents and shrinking pipelines of blockbuster drugs. In such cases orphan drugs bring forth a new business model.1
The total number of disease categorized as orphan are stands at about 7,000 currently, with nearly 250 new disease being appended to this list annually. 1
Download the whitepaper as provided by Mesned now to find out more about:
- Global Overview of Orphan Drug Market
- Healthcare in KSA
- Prevalence of Orphan Disease in MENA
- Orphan Drug Market in KSA
- Clinical Trial Opportunities
- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 – 2018.
MPCC is joining us the World Orphan Drug Congress USA 2015. It’s not too late to join them – simply click the banner below to book.